Latest & greatest articles for naproxen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on naproxen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on naproxen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for naproxen

21. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine

Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B CRD summary This review concluded that naproxen sodium was more effective than placebo, but might produce more adverse events, in the acute (...) treatment of moderate or severe migraine attacks in adults. Trials were needed to compare it with other active treatments. These conclusions reflect the results, but the small number of trials and omission of the trial selection process should be considered. Authors' objectives To determine the efficacy and safety of naproxen sodium in the treatment of acute migraine. Searching MEDLINE, EMBASE, EBM reviews, and the Cochrane Library were searched, without language restriction, for articles from

2010 DARE.

22. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life (PubMed)

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life To evaluate efficacy and tolerability of a single, fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan/naproxen sodium) vs placebo in migraineurs who had discontinued treatment with a short-acting triptan because of poor response or intolerance.Triptan monotherapy is ineffective or poorly tolerated in 1 of 3 migraineurs and in 2 of 5 migraine attacks. In April, 2008, the Food (...) and Drug Administration approved the combination therapy sumatriptan/naproxen sodium, developed specifically to target multiple migraine mechanisms. This combination product offers an alternative migraine therapy for patients who have reported poor response or intolerance to short-acting triptans.Two replicate, randomized, multicenter, double-blind, placebo-controlled, 2-attack crossover trials evaluated migraineurs who had discontinued a short-acting triptan in the past year because of poor response

2009 EvidenceUpdates

23. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI (PubMed)

Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI In a multicentre study to explore the effects of licofelone as a disease-modifying osteoarthritis drug in comparison with naproxen in patients with knee osteoarthritis (OA), using MRI and x-ray examination.Patients with knee OA (n = 355) were randomised to receive either licofelone (200 mg twice (...) a day) or naproxen (500 mg twice a day). MRI and x-ray examinations were performed at baseline, 6 months (MRI only), 12 and 24 months. MRI was used to assess quantitatively changes in cartilage volume, and x-ray examinations (Lyon-Schuss) to measure changes in the mean and minimum joint space width (JSW) in the medial compartment. Questionnaires probing symptoms were completed. Data were presented as intention to treat (ITT) and according to protocol (ATP).Cartilage volume loss in the global joint

2009 EvidenceUpdates

24. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine (PubMed)

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome.To investigate the efficacy and tolerability of a fixed-dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine.Patients (aged 18 to 65 years (...) ) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo. The primary efficacy measure was the percentage of patients who became pain-free 2 hours postdose.Intent-to-treat analyses consisted of 576 and 535 migraineurs. At 2

2008 EvidenceUpdates

25. Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib (Full text)

Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs.To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults.Randomized, double-masked chemoprevention trial.Six US memory clinics.Men and women aged 70 years and older (...) with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment.Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively.Seven tests of cognitive function and a global summary score measured annually.Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over

2008 EvidenceUpdates PubMed

26. Treximet (sumatriptan and naproxen sodium)

Treximet (sumatriptan and naproxen sodium) Drug Approval Package: Treximet (sumatriptan and naproxen sodium) NDA #021926 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Treximet (sumatriptan and naproxen sodium) Tablets Company: Pozen Inc. Application No.: 021926 Approval Date: 04/15/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) Medical Review(s) (PDF

2008 FDA - Drug Approval Package

27. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. (PubMed)

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Non-steroidal anti-inflammatory drugs and colchicine used to treat gout arthritis have gastrointestinal, renal, and cardiovascular adverse effects. Systemic corticosteroids might be a beneficial alternative. We investigated equivalence of naproxen and prednisolone in primary care.We did a randomised clinical trial to test equivalence of prednisolone and naproxen (...) for the treatment of monoarticular gout. Primary-care patients with gout confirmed by presence of monosodium urate crystals were eligible. 120 patients were randomly assigned with computer-generated randomisation to receive either prednisolone (35 mg once a day; n=60) or naproxen (500 mg twice a day; n=60), for 5 days. Treatment was masked for both patients and physicians. The primary outcome was pain measured on a 100 mm visual analogue scale and the a priori margin for equivalence set at 10%. Analyses were

2008 Lancet

28. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. (Full text)

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Multiple pathogenic mechanisms may be involved in generating the migraine symptom complex, and multimechanism-targeted therapy may confer advantages over monotherapy.To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate and naproxen sodium relative to efficacy and safety of each monotherapy and placebo for the acute treatment of migraine.Two replicate, randomized, double-blind, single (...) -attack, parallel-group studies conducted among 1461 (study 1) and 1495 (study 2) patients at 118 US clinical centers who were diagnosed as having migraine and received study treatment for a moderate or severe migraine attack.Patients were randomized in a 1:1:1:1 ratio to receive a single tablet containing sumatriptan, 85 mg, and naproxen sodium, 500 mg; sumatriptan, 85 mg (monotherapy); naproxen sodium, 500 mg (monotherapy); or placebo, to be used after onset of a migraine with moderate to severe

2007 JAMA PubMed

29. Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults (Full text)

Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults Article Text Treatment Review: a single dose of oral naproxen or naproxen sodium reduced acute

2006 Evidence-Based Nursing PubMed

30. Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs

Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs Article Text

2006 Evidence-Based Medicine (Requires free registration)

31. Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease (Full text)

Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease Article Text Therapeutics Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease Free Robin Jacoby

2004 Evidence-Based Mental Health PubMed

32. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. (PubMed)

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limited, and the possibility that these inhibitors increase cardiovascular events has been raised. The Therapeutic Arthritis Research (...) and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen.18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) for 52 weeks, in two substudies of identical design (lumiracoxib vs ibuprofen or naproxen). Randomisation

2004 Lancet

33. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. (PubMed)

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared (...) with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen.18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) in two substudies of identical design. Randomisation was stratified for low-dose aspirin use and age. The primary cardiovascular endpoint was the Antiplatelet Trialists' Collaboration endpoint of non-fatal and silent myocardial infarction

2004 Lancet

34. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. (Full text)

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease.To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (...) (naproxen) slows cognitive decline in patients with mild-to-moderate AD.Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications.Forty ambulatory treatment centers affiliated with the Alzheimer's Disease Cooperative Study consortium.Participants with mild-to-moderate AD (Mini-Mental State Examination score of 13-26) were recruited from December 1999 to November 2000 using clinic populations, referrals from community physicians, and local

2003 JAMA PubMed

35. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. (PubMed)

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. Many patients who have had upper gastrointestinal bleeding continue to take low-dose aspirin for cardiovascular prophylaxis or other non-steroidal antiinflammatory drugs (NSAIDs) for musculoskeletal pain. It is uncertain whether infection with Helicobacter pylori is a risk factor for bleeding in such patients.We studied patients with a history of upper (...) , and those who had been taking other NSAIDs were given 500 mg of naproxen twice daily for six months. The patients in each group were then randomly assigned separately to receive 20 mg of omeprazole daily for six months or one week of eradication therapy, consisting of 120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily, followed by placebo for six months.We enrolled 400 patients (250 of whom were taking aspirin and 150 of whom were taking other

2001 NEJM

36. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. (PubMed)

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID (...) naproxen among patients with rheumatoid arthritis.We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age and receiving long-term glucocorticoid therapy) and who had rheumatoid arthritis to receive either 50 mg of rofecoxib daily or 500 mg of naproxen twice daily. The primary end point was confirmed clinical upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers).Rofecoxib

2000 NEJM

37. Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. (Full text)

Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. To compare the clinical effectiveness of local corticosteroid injection, standard non-steroidal anti-inflammatory drugs, and simple analgesics for the early treatment of lateral epicondylitis in primary care.Multicentre pragmatic randomised controlled trial.23 general practices in North Staffordshire and South Cheshire.164 patients aged 18-70 (...) years presenting with a new episode of lateral epicondylitis.Local injection of 20 mg methylprednisolone plus lignocaine, naproxen 500 mg twice daily for two weeks, or placebo tablets. All participants received a standard advice sheet and co-codamol as required.Participants' global assessment of improvement (five point scale) at four weeks. Pain, function, and "main complaint" measured on 10 point Likert scales at 4 weeks, 6 months, and 12 months.Over 2 years, 53 subjects were randomised

1999 BMJ PubMed